ICPO Foundation

What ICPO Foundation does

ICPO Foundation is a German nonprofit organization (Stiftung des bürgerlichen Rechts) established in May 2019 and headquartered in Wiesbaden, with operational offices in Ravensburg. Its mission is to scale global patient access to Radiomolecular Precision Oncology, also known as Theranostics, a treatment modality that pairs diagnostic imaging (PET/CT, PET/MR) with targeted radiopharmaceutical therapy. The foundation focuses on low- and middle-income countries where access to Theranostics is most limited. It is governed by a Board of Trustees chaired by Udo J. Vetter and led by CEO Odile Jaume, with a Scientific Advisory Board of 19 experts across 9 countries.

ICPO operates an integrated platform built around four pillars: (1) the ICPO Theranostics Centers of Excellence Network, which has accredited over 50 diagnostic and therapeutic centers worldwide following international standards from leading nuclear medicine societies; (2) the ICPO Academy for Theranostics, a UEMS- and AMA-accredited e-learning platform offering certified CME in 10 languages with 800+ alumni from 30+ countries; (3) ICPO Research Support, which has disbursed EUR 1.6 million in grants since 2019, including EUR 225,000 in 2025; and (4) Community & Events, anchored by the biannual ICPO Forum at TUM Campus Garching (240+ attendees from 27 countries in 2025) and the annual Virtual Summit (400+ attendees in 2024). Additional tools include the ICPO Clinical Trial Finder and the Center Link portal connecting patients to accredited centers.

The business model is donation- and grant-driven, with funding sourced from corporate partners (Novartis, GE HealthCare, RayzeBio/BMS via the RLT Angels Association), individual donors, and member fees through the ICPO Friends program. Distribution is global and largely partnership-based: ICPO co-founded the RLT Angels Association in June 2025 alongside EANM, GE HealthCare, Novartis, and RayzeBio with a goal of reaching one million patients and 1,000 RLT centers worldwide. It holds strategic alliances with WFNMB, IAEA, AOFNMB, and SBMN, and is expanding geographically into North America (INITIO Medical, Vancouver), Latin America (UroTeragLATAM), and the Middle East. Pricing is non-commercial, with donations processed via PayPal, Stripe, and Wikando FundraisingBox.

Name

ICPO Foundation

Legal name

ICPO Foundation

Website

https://icpo.foundation

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

ICPO Foundation is a German nonprofit (founded 2019) that scales global patient access to Theranostics (Radiomolecular Precision Oncology) by accrediting a worldwide network of 50+ Centers of Excellence, delivering multilingual certified education through the ICPO Academy, funding research grants, and convening the global Theranostics community.

Ownership category

akta.pro rank

Product category

Precision Oncology Nonprofit Services

NAICS

Voluntary Health Organizations (813212), Educational Support Services (611710), Other Individual and Family Services (624190)

SIC

Services-Health Services (8000)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Investigator & Site Training / GCP Support (HLAGACAF), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ), Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Theranostics accreditation
• Precision oncology education
• Radiopharmaceutical therapy
• Nuclear medicine centers
• Cancer research grants

Headquarters

HQ city

Ravensburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Donations and Charitable Contributions: As a nonprofit organization, ICPO Foundation relies on donations from individuals and corporations to fund its mission of scaling global patient access to Theranostics. Donors can designate contributions to specific focus areas including Foundation Core Activities, ICPO Academy for Theranostics, or ICPO Science and Research.
2. Research Grants Funding: ICPO funds Theranostics-related grants to foster young talent innovation and center autonomy in translational research. Since 2019, ICPO has funded EUR 1.6 million in research grants, including EUR 225,000 in 2025.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

ICPO Foundation accredits and supports a global network of Theranostics Centers of Excellence (over 50 centers across multiple countries, with focus on low- and middle-income countries), delivers certified multilingual medical education through the ICPO Academy for Theranostics (UEMS/AMA accredited, 10 languages, 800+ alumni), funds Theranostics research grants (EUR 1.6 million since 2019), and organizes community events including the Virtual Summit and ICPO Forum to scale patient access to Radiomolecular Precision Oncology.

Product overview

The ICPO Foundation operates a platform model built around four interconnected core activities: (1) ICPO Theranostics Centers of Excellence Network - the cornerstone offering that develops and accredits international diagnostic and therapeutic centers; (2) ICPO Academy for Theranostics - a certified e-learning platform providing multilingual education; (3) ICPO Research Support - grant funding and awards program for scientific innovation; and (4) ICPO Community & Events - organizing flagship events like the ICPO Forum and Virtual Summit. Additional supporting tools include the Clinical Trial Finder. This integrated approach enables shared know-how, standardized education, and clinical best practices to improve patient access to Radiomolecular Precision Oncology (Theranostics) globally.

Differentiator

Problem solved

Functional benefit

Products and services

• ICPO Theranostics Centers of Excellence Network Global network of accredited diagnostic and therapeutic centers for Radiomolecular Precision Oncology (Theranostics). Centers undergo a structured accreditation process aligned with international standards from leading nuclear medicine societies, with particular focus on low- and middle-income countries. Members benefit from shared best practices, international visibility, and community support.
• ICPO Academy for Theranostics Certified continuing medical education platform in Theranostics. Accredited by the European Union of Medical Specialists (UEMS) and American Medical Association (AMA), endorsed by 11 international nuclear medicine societies with IAEA as a cooperation partner. Provides online lectures, clinical cases, and multidisciplinary tumor boards in 10 languages.
• ICPO Research Support (Research Grants Program)

Quantifiable outcome

• Grew from 11 to 50+ accredited centers in one year (2024-2025)
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and flagship.

• UroTeragLATAM FoundationcoreStrategic or Co-development Partner · 27 February 2026MoU signed to collaborate on advancing Theranostics education and improving patient access to precision oncology for urological cancers across Latin America. Combines ICPO's global expertise with UroTeragLATAM's regional leadership to expand ICPO Academy programs and identify candidates for new Theranostics centers throughout the region.
• World Federation of Nuclear Medicine and Biology (WFNMB)coreStrategic or Co-development Partner · 1 February 2026Strategic partnership to expand global access to precision oncology, particularly for patients in low- and middle-income countries. Aims to improve clinical standards, advance research, and enhance education through the ICPO Academy for Theranostics while supporting WHO resolution WHA78.13 on strengthening medical imaging capacity. ICPO also became an associate member of WFNMB.
• Oncidium FoundationcoreStrategic or Co-development Partner · 1 January 2026Sister foundation of ICPO that organized patient session at 8th Theranostics World Congress highlighting patient journeys. Through RLT-Connect program, helps expand patient access to Lu-177 PSMA therapy ensuring patients who might otherwise not have access can receive life-changing treatment.
• INITIO Medical (Vancouver, Canada)flagshipStrategic or Co-development Partner · 1 October 2025INITIO Medical recognized as the first ICPO Theranostics Clinical Center of Excellence in North America, specifically in Vancouver, Canada. Accreditation highlights its commitment to furthering Theranostics and improving patient access to advanced cancer treatments.
• Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB)coreStrategic or Co-development Partner · 7 August 2025AOFNMB officially endorsed the ICPO Academy for Theranostics during SNMMI Annual Meeting 2025. AOFNMB is committed to advancing nuclear medicine, molecular imaging, and radiopharmaceutical sciences across Asia and Oceania, fostering education, collaboration, and clinical excellence.
• Brazilian Society of Nuclear Medicine and Molecular Imaging (SBMN)coreStrategic or Co-development Partner · 31 July 2025Extended existing MoU to establish sustainable framework for accreditation and development of ICPO Clinical Theranostics Centers of Excellence in Brazil. Collaboration aims to improve nationwide patient access to Theranostics with focus on clinical standards optimization, targeted capacity building, and certified training programs.
• RLT Angels AssociationcoreStrategic or Co-development Partner · 20 June 2025ICPO co-founded the RLT Angels Association alongside EANM, GE HealthCare, Novartis, and RayzeBio (BMS) to improve access to radioligand imaging and therapies for up to one million patients globally. Initiative aims to establish 1,000 RLT Centers worldwide and develop open-source best practice resources, accreditation standards, and educational tools.
• GE HealthCarecoreStrategic or Co-development Partner · 20 June 2025Co-founding partner of RLT Angels Association. GE HealthCare contributes expertise in advanced imaging, radiopharmaceuticals, digital and clinical workflows, and operational excellence for radiotheranostics integration into everyday practice.
• NovartiscoreStrategic or Co-development Partner · 20 June 2025Co-founding partner of RLT Angels Association. Novartis demonstrates deep commitment to radiopharmaceutical therapy as an essential new pillar of Oncology with long-term plans across all aspects of the field.
• RayzeBio (a Bristol Myers Squibb company)coreStrategic or Co-development Partner · 20 June 2025Co-founding partner of RLT Angels Association. RayzeBio focuses on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
• European Association of Nuclear Medicine (EANM)coreStrategic or Co-development Partner · 1 June 2025Co-founding partner of RLT Angels Association. EANM is the largest non-profit medical organization dedicated to nuclear medicine in Europe, collaborating with professionals, national societies, EU institutions, international bodies, industry, and medical societies to leverage nuclear medicine's benefits for patient care.
• International Atomic Energy Agency (IAEA)coreStrategic or Co-development Partner · 1 January 2025Cooperation partner supporting WHO resolution WHA78.13 on strengthening medical imaging capacity. IAEA plays key role in global nuclear medicine initiatives and is involved in stakeholder meetings organized during WFNMB congress to implement the resolution.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Oncidium Foundation: Sister nonprofit foundation explicitly partnered with ICPO to expand patient access to Lu-177 PSMA therapy. Operates a near-identical model of patient access programs and global cancer theranostics advocacy, making it the closest organizational peer.
• World Federation of Nuclear Medicine and Biology (WFNMB): Global medical society that signed a 2026 strategic partnership with ICPO to advance theranostics worldwide and supports WHO resolution WHA78.13. Operates overlapping international education and standards work, but at the medical society level rather than as a foundation.
• Prostate Cancer Foundation: US-based disease-specific nonprofit that funds research and patient access programs for prostate cancer, including PSMA-targeted theranostics (a core ICPO indication). Operates a comparable nonprofit grantmaking and patient access model in an adjacent cancer vertical.
• RLT Angels Association: Public-private partnership co-founded by ICPO alongside EANM, Novartis, GE HealthCare, and RayzeBio in 2025 with a shared mission of expanding radioligand therapy access to 1 million patients globally. Most directly aligned operational peer in terms of mission and stakeholders.
• Stand Up To Cancer: US-based charitable program funding cancer research collaborations and translational grants. Operates a comparable donor-funded model for cancer research grants and clinical innovation, though with broader cancer-type scope and US-centric focus.

Broad incumbents

• European Association of Nuclear Medicine (EANM): Largest nonprofit medical organization for nuclear medicine in Europe and a co-founding partner of RLT Angels. Operates overlapping education, accreditation, and standard-setting activities for theranostics, but as a broader professional society with wider scope.
• Society of Nuclear Medicine and Molecular Imaging (SNMMI): US-based professional society that accredits nuclear medicine training and hosts major theranostics conferences. Provides overlapping educational and standard-setting functions but serves a broader nuclear medicine membership beyond ICPO's cancer-focused mission.
• International Atomic Energy Agency (IAEA): UN-affiliated international organization that is a cooperation partner with ICPO and runs global nuclear medicine capacity-building programs. Has overlapping LMIC-focused nuclear medicine and radiopharmaceutical initiatives but operates at intergovernmental scale.
• American Cancer Society: Large US-based health nonprofit that funds cancer research, patient access programs, and professional education across all cancer types. Addresses a broader mission but operates the same kind of donor-funded cancer research and patient access model.
• European Cancer Organisation: European umbrella cancer organization focused on cancer care quality, policy, and education across all cancer types. Overlaps with ICPO's mission of improving equitable cancer care access and standards but operates at a pan-European policy level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ICPO_Foundation
• YouTubeyoutube.com/channel/UCQlDIpdSUs_qXLlM2BOkS4A
• LinkedInde.linkedin.com/company/icpo-interna
• Instagraminstagram.com/icpo_foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICPO Foundation